Last reviewed 2026-04-20 · How we verify

Simponi

At a glance

Approved indications

• Ankylosing spondylitis
• Juvenile idiopathic arthritis
• Nonradiographic axial spondyloarthritis
• Polyarticular juvenile idiopathic arthritis
• Psoriasis with arthropathy
• Rheumatoid arthritis
• Ulcerative colitis

Common side effects

• Infections
• Upper respiratory tract infection
• Nasopharyngitis
• Injection site reactions
• ALT elevations ≥ 3 × ULN

Serious adverse events

• Sepsis
• Alanine aminotransferase increased
• Aspartate aminotransferase increased
• Tuberculosis
• ALT elevations ≥ 5 × ULN
• Anemia
• CNS demyelination
• Acute liver failure

Key clinical trials

• Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (PHASE2)
• A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (PHASE3)
• A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (PHASE2)
• An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis
• Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study (PHASE2)
• Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
• Stand UP to Rheumatoid Arthritis (SUPRA) (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.